G
Giuseppe Mancia
Researcher at University of Milano-Bicocca
Publications - 1465
Citations - 152794
Giuseppe Mancia is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Blood pressure & Ambulatory blood pressure. The author has an hindex of 145, co-authored 1369 publications receiving 139692 citations. Previous affiliations of Giuseppe Mancia include University of Milan & Instituto Politécnico Nacional.
Papers
More filters
Journal ArticleDOI
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Vlado Perkovic,Hiddo J.L. Heerspink,John Chalmers,Mark Woodward,Mark Woodward,Min Jun,Qiang Li,Stephen MacMahon,Stephen MacMahon,Mark E. Cooper,Pavel Hamet,Michel Marre,C. E. Mogensen,Neil Poulter,Giuseppe Mancia,Alan Cass,Anushka Patel,Sophia Zoungas,Sophia Zoungas +18 more
TL;DR: Improved glucose control will improve major kidney outcomes in patients with type 2 diabetes, and the progression of albuminuria was significantly reduced and its regression significantly increased.
Journal ArticleDOI
Blood Pressure Variability and Organ Damage in a General Population: Results from the PAMELA Study
Roberto Sega,Giovanni Corrao,Michele Bombelli,Luca Beltrame,Rita Facchetti,Guido Grassi,Marco M Ferrario,Giuseppe Mancia +7 more
TL;DR: In this article, the authors investigated the relationship between LVMI and 24-hour average blood pressure values in the population, and showed that there is a significant positive relationship with LVMI (beta = 0.38 and beta=0.88 for systolic and diastolic BP, respectively, P < 0.05 and P< 0.01).
Journal ArticleDOI
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Davide Soranna,Lorenza Scotti,Antonella Zambon,Cristina Bosetti,Guido Grassi,Alberico L. Catapano,Carlo La Vecchia,Giuseppe Mancia,Giovanni Corrao +8 more
TL;DR: Metformin, but not sulfonylurea, appears to reduce subsequent cancer risk, which has relevant implications in light of the exploding global epidemic of diabetes.
Journal ArticleDOI
Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation
Stefano Omboni,Gianfranco Parati,Paolo Palatini,Alessandro Vanasia,Maria Lorenza Muiesan,Cesare Cuspidi,Giuseppe Mancia +6 more
TL;DR: The results show that day–night blood pressure changes and the classification of patients into dippers and non-dippers are poorly reproducible over time and provides the first prospective evidence that treatment-induced changes in day-time blood pressure difference are not related to treatment- induced regression of left ventricular mass index.
Journal ArticleDOI
Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
Bastiaan E. de Galan,Bastiaan E. de Galan,Vlado Perkovic,Toshiharu Ninomiya,Avinesh Pillai,Anushka Patel,Alan Cass,Bruce Neal,Neil R Poulter,Stephen B. Harrap,Carl Erik Mogensen,Mark E. Cooper,Michel Marre,Bryan Williams,Pavel Hamet,Giuseppe Mancia,Mark Woodward,Paul Glasziou,Diederick E. Grobbee,Stephen MacMahon,John Chalmers +20 more
TL;DR: BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg, and a BP threshold below which renal benefit is lost is not identified.